BSE Live
Feb 11, 16:01Prev. Close
884.20
Open Price
899.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 11, 15:55Prev. Close
882.50
Open Price
884.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
875.60 (94)
| Profit & Loss account of Strides Pharma Science (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 2,049.37 | 2,062.24 | 1,762.44 | 1,919.21 | 1,795.45 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 2,049.37 | 2,062.24 | 1,762.44 | 1,919.21 | 1,795.45 | |
| Total Operating Revenues | 2,139.42 | 2,153.26 | 1,854.50 | 1,979.00 | 1,857.57 | |
| Other Income | 46.19 | 72.31 | 84.07 | 123.49 | 89.00 | |
| Total Revenue | 2,185.61 | 2,225.56 | 1,938.56 | 2,102.49 | 1,946.56 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 1,048.11 | 1,072.63 | 1,020.10 | 935.42 | 1,050.10 | |
| Purchase Of Stock-In Trade | 62.63 | 29.23 | 24.47 | 51.83 | 56.31 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -27.20 | 4.62 | 21.04 | 114.26 | -117.53 | |
| Employee Benefit Expenses | 377.59 | 335.21 | 267.01 | 272.09 | 272.72 | |
| Finance Costs | 145.91 | 167.93 | 138.68 | 74.24 | 65.34 | |
| Depreciation And Amortisation Expenses | 84.61 | 84.67 | 93.62 | 104.37 | 99.34 | |
| Other Expenses | 415.86 | 456.30 | 423.40 | 528.77 | 408.65 | |
| Total Expenses | 2,107.50 | 2,150.58 | 1,988.32 | 2,080.98 | 1,834.93 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 78.11 | 74.99 | -49.76 | 21.51 | 111.64 | |
| Exceptional Items | -0.03 | -5.37 | -15.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 78.08 | 69.62 | -64.76 | 21.51 | 111.64 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | -1.46 | 0.31 | -49.84 | -158.47 | 21.02 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 20.39 | 3.82 | -19.60 | -0.21 | 12.38 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 18.93 | 4.13 | -69.44 | -158.68 | 33.40 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 59.16 | 65.49 | 4.68 | 180.19 | 78.24 | |
| Profit/Loss From Continuing Operations | 59.16 | 65.49 | 4.68 | 180.19 | 78.24 | |
| Profit/Loss For The Period | 2,886.21 | 65.49 | 4.68 | 180.19 | 78.24 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 313.68 | 7.20 | 0.52 | 20.08 | 8.73 | |
| Diluted EPS (Rs.) | 313.65 | 7.19 | 0.52 | 20.07 | 8.72 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 22.99 | 13.55 | 0.00 | 0.00 | 17.91 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 40.00 | 25.00 | 0.00 | 0.00 | 25.00 |
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016